General
Preferred name
dihydroergotamine
Synonyms
DIHYDROERGOTAMINE MESYLATE ()
DIHYDROERGOTAMINE TARTRATE ()
Dihydroergotamine methanesulfonate ()
Dihydroergotamine (mesylate) ()
Trudhesa ()
Diergo ()
Dihydroergotamine Methanesulfonate ()
D.H.E. 45 ()
Migranal ()
Dihydergot ()
DHE-45 ()
Tonopan ()
NSC-759848 ()
Dihydroergotamine mesilate ()
MAP0004 ()
9,10-dihydroergotamine ()
Neomigran ()
MAP-0004 ()
P&D ID
PD010104
CAS
6190-39-2
5989-77-5
1381-02-8
511-12-6
Tags
drug
natural product
biased GPCR ligand
available
Approved by
FDA
First approval
1946
Drug Status
investigational
approved
Drug indication
Migraine
Anti-Adrenergic
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE
The major excretory route of dihydroergotamine is via the bile in the feces. ; Only 6%-7% of unchanged dihydroergotamine is excreted in the urine after intramuscular injection.
DESCRIPTION
Dihydroergotamine is an ergot alkaloid. It is used as a vasoconstrictor. The drug is administered as dihydroergotamine mesylate (PubChem CID 71171). The use of ergot alkaloids in the clinic has been discontinued or restricted due to their propensity to cause fibrosis.
(GtoPdb)
DESCRIPTION
Partial alpha agonist. Non-selective
(Tocriscreen Plus)
DESCRIPTION
Ergot alkaloid; vasoconstrictor; competitive serotonin receptor antagonist; partial agonist at alpha adrenoceptors and D2 dopamine receptors
(LOPAC library)
DESCRIPTION
Partial α agonist. Non-selective
(Tocriscreen Total)
DESCRIPTION
Muscarinic M3 antagonist
(Tocris Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
29
BiasDB
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Other bioactive compounds
Tocris Bioactive Compound Library
Tocriscreen Plus
Tocriscreen Total
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
66
Molecular Weight
583.28
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
4
Ring Count
8
Aromatic Ring Count
3
cLogP
2.08
TPSA
118.21
Fraction CSP3
0.48
Chiral centers
7.0
Largest ring
6.0
QED
0.43
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
7-TM Receptors
MOA
Adrenergic Receptor agonist
Adrenergic Receptor antagonist
Agonist
serotonin receptor agonist
Target
Serotonin 1d (5-HT1d) receptor
ADRA2A, DRD2, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7
5-HT Receptor
Primary Target
Non-selective Adrenergic ? Receptors
Indication
migraine headache
Therapeutic Class
Antimigraine Agents
Pathway
GPCR/G protein
Neuronal Signaling
Source data
